Biogen/BIIB

$198.18

-2.69%
-
1D1W1MYTD1YMAX

About Biogen

Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.

Ticker

BIIB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Christopher Viehbacher

Employees

7,570

Headquarters

Cambridge, United States

Biogen Metrics

BasicAdvanced
$28.81B
Market cap
24.84
P/E ratio
$7.98
EPS
0.01
Beta
-
Dividend rate
$28.81B
0.00911
$319.76
$197.78
1.16M
1.997
1.261
45.868
46.882
25.798
3.86%
4.52%
8.24%
5.2%
24.839
2.929
1.94
132.632
23.311
-3.32%
-61.86%
-9.89%
-31.49%

What the Analysts think about Biogen

Analyst Ratings

Majority rating from 36 analysts.
Buy

Price Targets

Average projection from 30 analysts.
51.85% upside
High $500.00
Low $215.00
$198.18
Current price
$300.93
Average price target

Biogen Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
10.46% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$2.39B
-5.69%
Net income
$249.7M
-466.67%
Profit margin
10.46%
-488.85%

Biogen Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.66%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$3.40
$4.02
$4.36
$3.30
-
Expected
$3.28
$3.77
$3.97
$3.18
$3.47
Surprise
3.69%
6.75%
9.74%
3.66%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Biogen stock?

Biogen (BIIB) has a market cap of $28.81B as of April 15, 2024.

What is the P/E ratio for Biogen stock?

The price to earnings (P/E) ratio for Biogen (BIIB) stock is 24.84 as of April 15, 2024.

Does Biogen stock pay dividends?

No, Biogen (BIIB) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Biogen dividend payment date?

Biogen (BIIB) stock does not pay dividends to its shareholders.

What is the beta indicator for Biogen?

Biogen (BIIB) has a beta rating of 0.01. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Biogen stock price target?

The target price for Biogen (BIIB) stock is $300.93, which is 51.85% above the current price of $198.18. This is an average based on projections from 30 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Biogen stock

Buy or sell Biogen stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing